• search
CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Monoclonal Antibody (mAb) Discovery Services

Monoclonal Antibody (mAb) Discovery Services

We offer wide range of technology platforms, screening tiers, fit-for-purpose tool and therapeutics for monoclonal antibody discovery (mAb).

A robust antibody discovery platform is an important core factor that determines the success of a set of drug modalities. The area of antibody discovery has seen tremendous technological advancement, offering pharma companies a wide range of tools to choose from. At Aurigene, we design our monoclonal antibody discovery programs keeping the therapeutic end point in mind and choose the technology platform accordingly.

Our team has experience in handling several technology platforms including humanized rodents, B-cell cloning, hybridoma, and display libraries. Fit-for-purpose tools and reagent monoclonal antibodies are generated to meet the program needs.

Speak to our experts

Antigen generation and Immunization strategies

  • RNA, membrane and whole cell immunization
  • Immunization with conjugate antigens
  • Immunization with whole-cell, recombinant cell lines, nano disc and membrane preparations
  • Immunization protocols; standard, RImMS and hybrid
  • Neonatal strategy for better epitope specificity and less immunogenic epitope
  • Display technologies: phage, yeast and mammalian: Under development
  • Strong expertise in anti-idiotypic antibody discovery (blockers/non-blockers with single digit nM/pM affinity) to support PK / ADA assays

Hybridoma and B-Cell cloning

  • Antigen-specific single B-cell sorting, sequencing / v-gene recovery, sub-cloning / reformatting, expression, screening and monoclonal selection
  • Enriched B-cell or target-specific B-cell fusion methodologies
  • Highly efficient and optimized fusion (PEG and electrofusion) technologies for generating hybridoma

Screening & evaluation strategies

  • Multitier high-throughput screening strategies using flow cytometry, ELISA, and octet
  • Analytical SE-HPLC, BIAcore, functional assay and mass spectrometry to support analytics
  • Functional assay & fit-for-purpose assay (IHC, Western blotting etc.) for evaluation

Why Aurigene Pharmaceutical Services?

Single B-cell cloning

Humanized rodent platform

Display platforms (Phage/ Yeast)


Contact Us

CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

JUNE 28, 2022

Neoantigen Specific T cells For Cancer Immunotherapy

Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...

Read More

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization

Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...

Read More

Technology meets sustainability - How a complex API development process goes green

We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...

Read More

Alternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug


Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...

Read More
View All

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.